Flanagan W. Michael

Chief Scientific OfficerAvidity Biosciences, Inc. (RNAM) · full profile →Form 4 · filed Feb 27, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
1 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 27, 2026Disposed to issuer(D)150K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 27, 2026Disposed to issuer(D)25K0
Feb 27, 2026Disposed to issuer(D)67K0
Feb 27, 2026Disposed to issuer(D)50K0
Feb 27, 2026Disposed to issuer(D)72K0
Feb 27, 2026Disposed to issuer(D)88K0
Feb 27, 2026Disposed to issuer(D)96K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-082261) within minutes of acceptance. Every field above traces to the original document. Verify it directly: